Presented by RGA
New results from the highly anticipated NHS-Galleri study show that the trial did not meet its primary endpoint of achieving a statistically significant reduction in combined Stage III and IV cancer diagnoses. While secondary findings offer more encouraging signals, particularly in detecting aggressive cancers, they warrant careful interpretation. RGA unpacks what these results mean for insurers today and what to watch as the landscape continues to evolve.